S 81694
Alternative Names: NMS P153; NMS-01940153; NMS-01940153E; NMS-153; S-81694Latest Information Update: 23 Jan 2025
At a glance
- Originator Nerviano Medical Sciences
- Developer Nerviano Medical Sciences; Servier
- Class Antineoplastics; Small molecules
- Mechanism of Action TTK protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Breast cancer; Liver cancer
- No development reported Acute myeloid leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma; Solid tumours
Most Recent Events
- 07 Jan 2025 Nerviano Medical Sciences plans a phase IIa trial for Liver cancer (Inoperable/unresectable, Second-line therapy or greater) in Italy and Spain (IV) (EUCT-2024-516737-12-00)
- 28 Dec 2024 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in France (IV)
- 28 Dec 2024 No recent reports of development identified for preclinical development in Precursor-B-cell-lymphoblastic-leukaemia-lymphoma in France